David Ellenberger
Overview
Explore the profile of David Ellenberger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
582
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jalusic K, Ellenberger D, Stahmann A, Berger K
Gesundheitswesen
. 2025 Feb;
PMID: 39954671
No abstract available.
2.
Akmatov M, Graf J, Kohring C, Ellenberger D, Batzing J, Tremlett H, et al.
JAMA Netw Open
. 2024 Dec;
7(12):e2452652.
PMID: 39729316
Importance: A growing body of literature suggests the presence of a prodromal period with nonspecific signs and symptoms before onset of multiple sclerosis (MS). Objective: To systematically assess diseases and...
3.
Menssen M, Dammann M, Fneish F, Ellenberger D, Schaarschmidt F
Pharm Stat
. 2024 Oct;
24(2):e2447.
PMID: 39475336
In pre-clinical and medical quality control, it is of interest to assess the stability of the process under monitoring or to validate a current observation using historical control data. Classically,...
4.
Frahm N, Ellenberger D, Stahmann A, Fneish F, Luftenegger D, Salmen H, et al.
Ther Adv Neurol Disord
. 2024 Apr;
17:17562864241239740.
PMID: 38560408
Background: The spectrum of disease-modifying therapies (DMTs) for people with multiple sclerosis (PwMS) has expanded over years, but data on treatment strategies is largely lacking. DMT switches are common clinical...
5.
Goereci Y, Ellenberger D, Rommer P, Dunkl V, Golla H, Zettl U, et al.
J Neurol
. 2024 Mar;
271(6):3409-3416.
PMID: 38517521
Background: Persons with MS (PwMS) ≥ 55 years are underrepresented in therapy studies leading to a lack of evidence. Objective And Methods: To study the subgroup of PwMS ≥ 55 ...
6.
Stahmann A, Craig E, Ellenberger D, Fneish F, Frahm N, Marrie R, et al.
Ther Adv Neurol Disord
. 2024 Mar;
17:17562864241233044.
PMID: 38495364
Background: Treatment guidelines recommend early disease-modifying therapy (DMT) initiation after diagnosis of multiple sclerosis (MS). Multinational comparative studies that assess time to DMT initiation in MS may allow detection of...
7.
Fneish F, Frahm N, Peters M, Ellenberger D, Haas J, Lobermann M, et al.
Vaccines (Basel)
. 2023 Dec;
11(12).
PMID: 38140262
Several studies reported post-SARS-CoV-2-vaccination (PV) symptoms. Even people with multiple sclerosis (PwMS) have concerns about disease activity following the SARS-CoV-2 vaccination. We aimed to determine the proportion of PwMS with...
8.
Grothe M, Ellenberger D, Rommer P, Stahmann A, Zettl U
Ther Adv Neurol Disord
. 2023 Oct;
16:17562864231192826.
PMID: 37808247
Background: Epileptic seizures can occur throughout the course of multiple sclerosis (MS) and are associated with increasing disability progression over time. However, there are no data on whether epileptic seizures...
9.
Nicholas R, Rodgers J, Witts J, Lerede A, Friede T, Hillert J, et al.
Ther Adv Neurol Disord
. 2023 Sep;
16:17562864231198963.
PMID: 37771841
Introduction: Prescribing guidance for disease-modifying treatment (DMT) in multiple sclerosis (MS) is centred on a clinical diagnosis of relapsing-remitting MS (RRMS). DMT prescription guidelines and monitoring vary across countries. Standardising...
10.
Fneish F, Ellenberger D, Frahm N, Stahmann A, Fortwengel G, Schaarschmidt F
Ther Innov Regul Sci
. 2023 Jul;
57(6):1217-1228.
PMID: 37450198
Monitoring of clinical trials is a fundamental process required by regulatory agencies. It assures the compliance of a center to the required regulations and the trial protocol. Traditionally, monitoring teams...